This study found that clinicians prescribe multiple treatments including EGFR TKIs to NSCLC patients with EGFR exon20ins despite known poor response rates, demonstrating the need for additional treatment options and further collaboration with practitioners. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.